MedTrace Logo

Lactobacillus Farciminis and Hyperalgesia

NCT00852865 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2009-05-01

No results posted yet for this study

Summary

We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.

Conditions

Interventions

DRUG

Lactobacillus farciminis

1 capsule per day. Each capsule containing 4\*109 CFU

DRUG

Placebo

1 capsule per day

Sponsors & Collaborators

  • Lallemand SAS

    lead INDUSTRY

Principal Investigators

  • Claude DUBRAY, Professor · CPC/CIC-INSERM 501

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852865 on ClinicalTrials.gov